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Editorial on the Research Topic
The Role of HMGB1 in Immunity
High mobility group box 1 (HMGB1) is an evolutionarily conserved nuclear protein that can be
released by almost all cell types. Scientists have uncovered a variety of molecular mechanisms
by which HMGB1 in both immune and non-immune cells modulates the nature and magnitude
of immune responses (1–3). In recent years, HMGB1-targeted therapies have been exploited in
multiple preclinical studies of inflammatory conditions and there is robust clinical evidence for
HMGB1 levels as a potential biomarker for early prediction or progression of various diseases.
However, it is not presently possible to specifically target HMGB1 in any clinical setting. A
significant obstacle to developing therapeutics lies in gaps in knowledge of the post-translational
modification of HMGB1 as well as the timing and type of microenvironments to which HMGB1
is exposed.
This Research Topic provides a comprehensive overview of current understanding of the
contribution of HMGB1 to various diseases and HMGB1 specific therapeutics. Nine articles are
included: five original articles, three review articles, and one mini-review. The authors invited
the scientific contributors to this collection based on their unique and pioneering discoveries on
the role of HMGB1 in physiological and pathological conditions including: (i) HMGB1-related
immune functions (ii) Post-translational modification and secretion mechanisms of HMGB1 (iii)
Molecular pathways activated by HMGB1 in acute lung injury, lupus, cancers, and other diseases
(iv) Agents to modulate HMGB1 function.
HMGB1-RELATED IMMUNE FUNCTIONS
While many researchers have focused on HMGB1 as an inflammatory mediator that prolongs
various inflammatory diseases, another aspect of HMGB1, which is related to its role in tissue
healing and regeneration, is being highlighted (4, 5). Yamashiro et al. describe the potential
tolerogenic role of HMGB1 in periodontal disease progress, including the cause of inflammation
and, conversely, regeneration of periodontal tissue. Further studies are needed regarding HMGB1
isoforms and their receptors that play major roles in the oral cavity to open up opportunities
for therapeutics.
Serum HMGB1 is elevated in systemic lupus erythematosus (SLE) patients, and it correlates
with disease activity (6). There are several preclinical studies of HMGB1-specific antagonists in
experimental lupus models showing inconsistent results. Liu et al. provide a mini-review about
the role of HMGB1 in SLE disease phenotypes and a novel agent forcing anti-inflammatory
macrophages polarization.
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In the tumor microenvironment, HMGB1 has a protective
role in cancer immunity during the early stage of disease.
In contrast, sustained HMGB1 recruits immunosuppressive
myeloid-derived suppressor cells and regulatory T cells during
tumor progression (7). Soloff et al. provide insight into how
HMGB1 impacts the microenvironment of malignant pleural
effusions (MPEs). The level of HMGB1 was inversely correlated
to the diversity of γδ T cells in MPE. The authors suggest some
novel therapeutic strategies for targeted HMGB1-neutralization
and its usage in pleural effusions.
POST-TRANSLATIONAL MODIFICATION
AND SECRETION MECHANISMS OF
HMGB1
The dynamics of HMGB1 oxidation in health and disease
are unknown. Ferrara et al. confirmed our understanding of
functions of HMGB1 redox isoforms using novel applications
of in vivo-based assay. They demonstrate that the redox state of
HMGB1 is controlled at both tissue and cell levels, suggesting that
HMGB1 oxidation is a spatially regulated process. Kwak et al.
provide an overview of the protein secretion mechanisms. The
authors highlight the importance of multiple post-translational
modifications and the redox biology of HMGB1, focusing on the
vital role of HMGB1 oxidation in its secretion.
MOLECULAR PATHWAYS BY HMGB1 IN
HUMAN DISEASES
Sepsis is a life-threatening inflammatory condition with no
known cure. HMGB1 is a critical mediator of acute and
chronic inflammation in sepsis caused by endotoxin (8). Li
W. et al. assess a novel mechanism through which hepatocytes
secrete HMGB1 following LPS stimulation that is relevant to
sepsis pathogenesis and inflammatory diseases of the liver. The
cytoplasmic translocation and later release of HMGB1 from
hepatocytes are mediated by a TLR4, Caspase-11, and Gasdermin
D-dependent mechanism. HMGB1 is secreted in exosomes.
Kim et al. demonstrate the anti-inflammatory effect of sulfatide
in suppressing the secretion of HMGB1 and disrupting lipid
rafts following LPS stimulation. They suggest that sulfatide is
a potential therapeutic agent against sepsis. Li R. et al. explore
how HMGB1/PI3K/Akt/mTOR signaling participates in acute
lung injury and acute respiratory distress syndrome which are
characterized by persistent hypoxemia, disruption of the alveolar-
capillary barrier, and widespread inflammation in the lung.
AGENTS TO MODULATE HMGB1
FUNCTION
As mentioned above, HMGB1 antagonists have achieved
therapeutic success in a broad set of preclinical inflammatory
disease animal models. Yang et al. summarize recent advances in
the understanding of HMGB1 as a pro-inflammatory molecule.
Collectively, these articles provide information for other
researchers in the field that will eventually help develop novel
therapeutic approaches to regulate the function of HMGB1
for the benefit of patients. The next step should be to
translate these preclinical studies into clinical settings. Many
inflammatory diseases, including the current pandemic COVID-
19, are characterized by increased circulating HMGB1 levels
(9). HMGB1 possibly plays a role in the increased risk for
severe outcomes in COVID-19 patients with inflammatory
comorbidities. Overall, HMGB1 is relevant in many diseases and
research on HMGB1 can benefit all fields of medicine.
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